Overview
FAQs
Research Feed
Update History
References2026-07-05
Page created majorIntervention page (canonical structure): Overview + Mechanism of Action, Conditions (with the ReBUILD evidence), FAQs, and Research Feed.
Did you know?
Clemastine, a decades-old over-the-counter antihistamine, was the first drug shown to reverse a measure of demyelination in a clinical trial. It works not on the immune system but on the brain's own myelin-repair cells.
Clemastine Fumarate
Clemastine fumarate is a first-generation antihistamine with antimuscarinic activity, repurposed in neurology as a remyelinating agent that drives myelin-forming cells to mature.
Page Snapshot
Microbiome-targeted interventions (MBTIs) are validated using a dual-evidence logical framework. First, the intervention must realign the condition’s microbiome signature by increasing beneficial taxa that are consistently depleted and reducing pathogenic taxa that are consistently enriched. Second, the intervention must demonstrate measurable clinical benefit. Concordance of these effects in the same context validates the intervention as an MBTI and supports the clinical relevance of the microbiome signature.
Karen Pendergrass
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreOverview
Clemastine fumarate is an inexpensive, widely available first-generation antihistamine (an H1 antagonist) that also has antimuscarinic activity. Beyond its allergy indication, it has drawn attention in neurology as a remyelinating agent: it acts on the cells that build myelin rather than on the immune system. As a sedating anticholinergic, its usual adverse effects are drowsiness and dry mouth. It is a repair-directed therapy, complementary to disease-modifying and microbiome-targeted approaches, and does not replace them.
Mechanism of Action
Clemastine's remyelinating action comes from its antimuscarinic (anticholinergic) property, not its antihistamine one. A high-throughput screen for remyelinating compounds identified antimuscarinic agents, clemastine among them, that release the differentiation block on oligodendrocyte precursor cells, driving them to mature into myelin-forming oligodendrocytes.[1] The result is remyelination of denuded axons.
Conditions
Clemastine's characterized use is in multiple sclerosis, where the target is repair of the myelin sheath rather than the immune attack.
| Condition | Findings | MBTI Status |
|---|---|---|
| Multiple Sclerosis | In the ReBUILD crossover trial, clemastine met its primary endpoint, shortening visual-evoked-potential latency, an electrophysiological signal of remyelination in the optic nerve.[2] | Promising Candidate |
ReBUILD randomized 50 people with relapsing MS and chronic optic neuropathy to clemastine or placebo in a crossover design; clemastine shortened visual-evoked-potential latency by roughly 1.7 milliseconds per eye, the first demonstration of myelin repair in a human MS trial, though it mildly worsened fatigue.[2]
FAQs
What is Clemastine Fumarate?
Quick answer: Clemastine fumarate is an inexpensive, widely available first-generation antihistamine (an H1 antagonist) that also has antimuscarinic activity. Beyond its allergy indication, it has drawn attention in neurology as a remyelinating agent: it acts on the cells that build myelin rather than on the immune system. As a sedating anticholinergic, its usual adverse effects are drowsiness and dry mouth. It is a repair-directed therapy, complementary to disease-modifying and microbiome-targeted approaches, and does not replace them.
How does Clemastine Fumarate work?
Quick answer: Clemastine's remyelinating action comes from its antimuscarinic (anticholinergic) property, not its antihistamine one. A high-throughput screen for remyelinating compounds identified antimuscarinic agents, clemastine among them, that release the differentiation block on oligodendrocyte precursor cells, driving them to mature into myelin-forming oligodendrocytes. [1] The result is remyelination of denuded axons.
What conditions can Clemastine Fumarate help?
Quick answer: Clemastine's characterized use is in multiple sclerosis, where the target is repair of the myelin sheath rather than the immune attack.
Research Feed
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD)
2017
The first trial to show a therapy repairing myelin in people with MS, using an old antihistamine.
What was studied?
Whether clemastine fumarate, an antimuscarinic antihistamine, promotes remyelination in multiple sclerosis, measured by visual evoked potential latency.
Who was studied?
Fifty people with relapsing MS and chronic optic neuropathy, in a randomized, double-blind, placebo-controlled crossover trial.
What were the key findings?
Clemastine met its primary endpoint, shortening visual-evoked-potential latency by about 1.7 milliseconds per eye, the first demonstration of myelin repair in a human MS trial. Fatigue was mildly worsened.
What are the implications?
Remyelination is a measurable, achievable target in MS, and antimuscarinic agents such as clemastine can drive it, complementing immune-directed therapy.
Update History
References
- Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Mei F, Fancy SPJ, Shen YA, et al. (Nat Med. 2014)
- Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Green AJ, Gelfand JM, Cree BA, et al. (Lancet. 2017)
Reference [1]
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
Mei F, Fancy SPJ, Shen YA, et al. Nat Med. 2014
View sourceReference [2]
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
Green AJ, Gelfand JM, Cree BA, et al. Lancet. 2017
View source